| The potential for treatment shortening with higher rifampicin doses: relating drug exposure to treatment response in patients with pulmonary tuberculosis EM Svensson, RJ Svensson, LHM Te Brake, MJ Boeree, N Heinrich, ... Clinical Infectious Diseases 67 (1), 34-41, 2018 | 101 | 2018 |
| Pharmacokinetic/pharmacodynamic analysis of an intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis L Te Brake, S Dian, AR Ganiem, C Ruesen, D Burger, R Donders, ... International journal of antimicrobial agents 45 (5), 496-503, 2015 | 97 | 2015 |
| Pharmacokinetics, tolerability, and bacteriological response of rifampin administered at 600, 900, and 1,200 milligrams daily in patients with pulmonary tuberculosis RE Aarnoutse, GS Kibiki, K Reither, HH Semvua, F Haraka, CM Mtabho, ... Antimicrobial agents and chemotherapy 61 (11), 10.1128/aac. 01054-17, 2017 | 94 | 2017 |
| Double-blind, randomized, placebo-controlled phase II dose-finding study to evaluate high-dose rifampin for tuberculous meningitis S Dian, V Yunivita, AR Ganiem, T Pramaesya, L Chaidir, K Wahyudi, ... Antimicrobial agents and chemotherapy 62 (12), 10.1128/aac. 01014-18, 2018 | 86 | 2018 |
| High-dose rifampicin in tuberculosis: experiences from a Dutch tuberculosis centre C Seijger, W Hoefsloot, I Bergsma-de Guchteneire, L Te Brake, ... PLoS One 14 (3), e0213718, 2019 | 80 | 2019 |
| Model-based meta-analysis of rifampicin exposure and mortality in Indonesian tuberculous meningitis trials EM Svensson, S Dian, L Te Brake, AR Ganiem, V Yunivita, ... Clinical Infectious Diseases 71 (8), 1817-1823, 2020 | 75 | 2020 |
| The role of efflux pumps in tuberculosis treatment and their promise as a target in drug development: unraveling the black box LHM Te Brake, GJ de Knegt, JE de Steenwinkel, TJP Van Dam, ... Annual review of pharmacology and toxicology 58 (1), 271-291, 2018 | 75 | 2018 |
| High-dose oral and intravenous rifampicin for the treatment of tuberculous meningitis in predominantly human immunodeficiency virus (HIV)-positive Ugandan adults: a phase II … FV Cresswell, DB Meya, E Kagimu, D Grint, L Te Brake, J Kasibante, ... Clinical Infectious Diseases 73 (5), 876-884, 2021 | 68 | 2021 |
| Intensified antibiotic treatment of tuberculosis meningitis FV Cresswell, L Te Brake, R Atherton, R Ruslami, KE Dooley, ... Expert review of clinical pharmacology 12 (3), 267-288, 2019 | 63 | 2019 |
| Increased bactericidal activity but dose-limiting intolerability at 50 mg· kg− 1 rifampicin LHM Te Brake, V de Jager, K Narunsky, N Vanker, EM Svensson, ... European Respiratory Journal 58 (1), 2021 | 52 | 2021 |
| A category approach to predicting the developmental (neuro) toxicity of organotin compounds: the value of the zebrafish (Danio rerio) embryotoxicity test (ZET) AB van Woudenberg, A Wolterbeek, L Te Brake, C Snel, A Menke, ... Reproductive toxicology 41, 35-44, 2013 | 51 | 2013 |
| Inhibitory potential of tuberculosis drugs on ATP-binding cassette drug transporters LHM Te Brake, FGM Russel, JJMW van den Heuvel, GJ de Knegt, ... Tuberculosis 96, 150-157, 2016 | 49 | 2016 |
| Xpert MTB/RIF ultra for the diagnosis of tuberculous meningitis: a small step forward J Donovan, FV Cresswell, NTT Thuong, DR Boulware, GE Thwaites, ... Clinical Infectious Diseases 71 (8), 2002-2005, 2020 | 47 | 2020 |
| Management of intracranial tuberculous mass lesions: how long should we treat for? S Marais, R Van Toorn, FC Chow, A Manesh, OK Siddiqi, A Figaji, ... Wellcome open research 4, 2019 | 37 | 2019 |
| Moxifloxacin Is a Potent In Vitro Inhibitor of OCT- and MATE-Mediated Transport of Metformin and Ethambutol LHM Te Brake, JJMW van den Heuvel, AO Buaben, R van Crevel, A Bilos, ... Antimicrobial agents and chemotherapy 60 (12), 7105-7114, 2016 | 33 | 2016 |
| Exposure to total and protein-unbound rifampin is not affected by malnutrition in Indonesian tuberculosis patients LHM te Brake, R Ruslami, H Later-Nijland, F Mooren, M Teulen, L Apriani, ... Antimicrobial agents and chemotherapy 59 (6), 3233-3239, 2015 | 33 | 2015 |
| Rifampicin alters metformin plasma exposure but not blood glucose levels in diabetic tuberculosis patients LHM Te Brake, V Yunivita, R Livia, N Soetedjo, ... Clinical Pharmacology & Therapeutics 105 (3), 730-737, 2019 | 31 | 2019 |
| Determination of protein-unbound, active rifampicin in serum by ultrafiltration and ultra performance liquid chromatography with UV detection. A method suitable for standard … EWJEB Kolmer, MJA Teulen, ECA van den Hombergh, NE van Erp, ... Journal of Chromatography B 1063, 42-49, 2017 | 31 | 2017 |
| New and repurposed drugs for the treatment of active tuberculosis: an update for clinicians JM Aguilar Diaz, AA Abulfathi, LH Te Brake, J van Ingen, S Kuipers, ... Respiration 102 (2), 83-100, 2023 | 25 | 2023 |
| Protein binding of rifampicin is not saturated when using high-dose rifampicin CHC Litjens, RE Aarnoutse, EWJ van Ewijk-Beneken Kolmer, ... Journal of Antimicrobial Chemotherapy 74 (4), 986-990, 2019 | 23 | 2019 |